肠道菌群与代谢组学在心血管疾病研究中的新进展
摘要
代谢组学技术通过高通量测序和数据分析对生物体液内的代谢物进行定性定量分析，发现生物标志物并帮助阐明疾病的发
生机制，为疾病的早期诊断 / 预防及治疗提供新思路。在本篇综述中主要阐述应用代谢组学技术对肠道菌群及其代谢产物
进行定性定量分析，讨论可能与心血管疾病发生发展相关的相关代谢产物及菌群及其可能的发生机制，综合整理肠道菌与
代谢组学在心血管疾病研究的新进展。
关键词
全文:
PDF参考
[1] Roth, G.A., et al., Global burden of cardiovascular
diseases and risk factors, 1990–2019: update from the GBD 2019
study. Journal of the American college of cardiology, 2020. 76(25):
p. 2982-3021.
[2] Nemet, I., et al., A Cardiovascular Disease-Linked Gut
Microbial Metabolite Acts via Adrenergic Receptors. Cell, 2020.
180(5): p. 862-877.e22.
[3] Fan, L., et al., Alterations of Gut Microbiome,
Metabolome, and Lipidome in Takayasu Arteritis. Arthritis
Rheumatol, 2023. 75(2): p. 266-278.
[4] Opazo, M.C., et al., Intestinal Microbiota Influences
Non-intestinal Related Autoimmune Diseases. Frontiers in
Microbiology, 2018. 9.
[5] 蔡昭玲 , 慢性心力衰竭患者肠道微生物菌群及其血
清代谢组学研究 . 2021
[6] Agus, A., J. Planchais, and H. Sokol, Gut Microbiota
Regulation of Tryptophan Metabolism in Health and Disease. Cell
Host & Microbe, 2018. 23(6): p. 716-724.
[7] Cheong, J.E. and L. Sun, Targeting the IDO1/TDO2-
KYN-AhR Pathway for Cancer Immunotherapy - Challenges and
Opportunities. Trends Pharmacol Sci, 2018. 39(3): p. 307-325.
[8] Krishnan, S., et al., Gut Microbiota-Derived Tryptophan
Metabolites Modulate Inflammatory Response in Hepatocytes and
Macrophages. Cell Reports, 2018. 23(4): p. 1099-1111.
[9] Deng, X., et al., Cardiovascular Benefits of Empagliflozin
Are Associated With Gut Microbiota and Plasma Metabolites in
Type 2 Diabetes. J Clin Endocrinol Metab, 2022. 107(7): p. 1888-
1896.
[10] Nicholson, J.K., J.C. Lindon, and E. Holmes,
‘Metabonomics’: understanding the metabolic responses
of living systems to pathophysiological stimuli via multivariate
statistical analysis of biological NMR spectroscopic data.
Xenobiotica, 1999. 29(11): p. 1181-9.
[11] Furukawa, N., et al., Soy protein β-conglycinin
ameliorates pressure overload-induced heart failure by increasing
short-chain fatty acid (SCFA)-producing gut microbiota and
intestinal SCFAs. Clinical Nutrition, 2024. 43(12): p. 124-137.
[12] 邹琳 , 李 .A. 张 .A., 基于基因组学与代谢组学分析
肠道菌群及其代谢物改变与心力衰竭发生的相关性 . 安徽医
科大学学报 , 2022. 57(3).
[13] Li, J., et al., Shifts in gut microbiome and metabolome
are associated with risk of recurrent atrial fibrillation. J Cell Mol
Med, 2020. 24(22): p. 13356-13369.
[14] 郑淑芬 , 吴圆圆 , and 钟诗龙 , 基于肠道菌群参与
的冠心病色氨酸代谢通路研究现状 . 中国临床药理学杂志 ,
2020. 36(20): p. 3362-3366..
[15] Kouzu, H., et al., Adverse plasma branched-chain amino
acid profile mirrors fatty muscle degeneration in diabetic heart
failure patients. ESC Heart Fail, 2024. 11(5): p. 2941-2953.
[16] Naeem, F., et al., Targeted Quantitative Plasma
Metabolomics Identifies Metabolite Signatures that Distinguish
Heart Failure with Reduced and Preserved Ejection Fraction.
medRxiv, 2024.
[17] Selvaraj, S., et al., Targeted Metabolomic Profiling of
Dapagliflozin in Heart Failure With Preserved Ejection Fraction:
The PRESERVED-HF Trial. JACC Heart Fail, 2024. 12(6): p.
999-1011.
[18] 梁兆颖 , 基于代谢组学与 16SrDNA 技术探索慢性心
力衰竭湿证生物学标志物的研究 . 2023.
[19]Kong, Q., et al., Alterations of the gut microbiome and
metabolic profile in CVB3-induced mice acute viral myocarditis.
BMC Microbiol, 2023. 23(1): p. 139.
(10 摘要 Views, 51 PDF Downloads)
Refbacks
- 当前没有refback。